Fusidic acid oral - Melinta Therapeutics

Drug Profile

Fusidic acid oral - Melinta Therapeutics

Alternative Names: CEM-102; SQ-16603; Taksta

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Cempra Pharmaceuticals; Melinta Therapeutics
  • Class Antibacterials; Cholestadienes; Sterols
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone and joint infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase II/III Bone and joint infections
  • No development reported Cystic fibrosis-associated respiratory tract infections; Osteomyelitis

Most Recent Events

  • 06 Nov 2017 Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections(In children) in USA (PO, Suspension)
  • 09 Aug 2017 Cempra completes enrolment in its phase II/III trial for Bone and joint infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top